Rivaroxaban

CAS 366789-02-8 82 current records 2 historicalSmall Molecule

Who holds supplier records for Rivaroxaban? 82 organisations hold a current record for Rivaroxaban: an active US FDA Type II Drug Master File or a CEP. A further 2 organisations have only historical (inactive) DMF filings. 62 of them hold a valid EU Certificate of Suitability (61 holder entries on the EDQM register, listed below). Recorded organisation countries for current records: India (46), China (15), Spain (3), Germany (1) and 9 other countries (9); not recorded for 8.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Rivaroxaban: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/rivaroxaban

Reading the evidence

  • 82 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    46 of the 74 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 39 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Rivaroxaban expires 6 Aug 2044. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (82)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Rivaroxaban. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Rivaroxaban sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (61)

Certificates of Suitability on the EDQM register for Rivaroxaban, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 69 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
GOLD PHARMA PRIVATE LIMITED Anakapalli DistrictIN
CEP 2025-554 - Rev 00
Rivaroxaban
Oct 2026—
ZHEJIANG SYNCOTIDE BIO-PHARMACEUTICAL CO., LTD. ShaoxingCN
CEP 2021-050 - Rev 01
Rivaroxaban
Oct 2026Inspected Oct 2024
Belgium
MICRO LABS LIMITED BengaluruIN
CEP 2023-290 - Rev 02
Rivaroxaban, Micronised
Sept 2026—
TITAN PHARMAPLUS PRIVATE LIMITED MahadIN
CEP 2025-240 - Rev 00
Rivaroxaban
Sept 2026—
MOEHS IBERICA S.L. RubiES
CEP 2021-245 - Rev 03
Rivaroxaban, Micronised
Aug 2026—
WANBURY LIMITED ThaneIN
CEP 2025-298 - Rev 00
Rivaroxaban
Jul 2026—
NEULAND LABORATORIES LIMITED HyderabadIN
CEP 2021-045 - Rev 02
Rivaroxaban, Form I
Jul 2026—
VIYASH SCIENTIFIC LIMITED HyderabadIN
CEP 2025-385 - Rev 02
Rivaroxaban, Process-2, RVS
Jul 2026—
CHIERON ACTIVE INGREDIENTS PRIVATE LIMITED HyderabadIN
CEP 2024-452 - Rev 00
Rivaroxaban, Micronised
Jun 2026—
QUIMICA SINTETICA S.A. Alcala De HenaresES
CEP 2020-405 - Rev 01
Rivaroxaban, Non-micronised and Micronised
Jun 2026Inspected Apr 2025
Spain
OPTIMUS DRUGS PRIVATE LIMITED HyderabadIN
CEP 2021-201 - Rev 01
Rivaroxaban
May 2026—
MATRIX PHARMACORP PRIVATE LIMITED SangareddyIN
CEP 2021-259 - Rev 04
Rivaroxaban, Modification-I
May 2026—
ALIVUS LIFE SCIENCES LIMITED MumbaiIN
CEP 2022-021 - Rev 01
Rivaroxaban
May 2026—
ALEMBIC PHARMACEUTICALS LIMITED VadodaraIN
CEP 2021-376 - Rev 01
Rivaroxaban, Process II
May 2026—
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Starogard GdanskiPL
CEP 2021-270 - Rev 04
Rivaroxaban, Non-micronised, Micronised
Apr 2026Inspected Jul 2026
Poland
CADILA PHARMACEUTICALS LIMITED AnkleshwarIN
CEP 2025-140 - Rev 00
Rivaroxaban, Form-I
Apr 2026—
KOPRAN RESEARCH LABORATORIES LIMITED MumbaiIN
CEP 2025-028 - Rev 00
Rivaroxaban
Apr 2026—
DONGBANG FUTURE TECH & LIFE CO., LTD. Hwaseong-SiKR
CEP 2021-211 - Rev 01
Rivaroxaban
Mar 2026—
BAJAJ HEALTHCARE LIMITED ThaneIN
CEP 2023-085 - Rev 01
Rivaroxaban
Mar 2026—
DIJIA PHARMACEUTICAL GROUP CO., LTD. WeihaiCN
CEP 2024-174 - Rev 00
Rivaroxaban
Feb 2026—
NOSCH LABS PRIVATE LIMITED HyderabadIN
CEP 2022-110 - Rev 01
Rivaroxaban
Feb 2026—
HETERO DRUGS LIMITED HyderabadIN
CEP 2023-231 - Rev 02
Rivaroxaban
Feb 2026—
JUBILANT BIOSYS LIMITED MysuruIN
CEP 2021-178 - Rev 01
Rivaroxaban
Jan 2026—
ZHEJIANG JINHUA CONBA BIO-PHARM. CO., LTD. Jinhua CityCN
CEP 2024-021 - Rev 00
Rivaroxaban, Micronised
Jan 2026—
ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. TaizhouCN
CEP 2021-017 - Rev 01
Rivaroxaban, Micronised, non-micronised
Dec 2025Inspected May 2026
Italy
AMI LIFESCIENCES PRIVATE LIMITED VadodaraIN
CEP 2022-215 - Rev 02
Rivaroxaban
Nov 2025Inspected Oct 2025
Slovakia
Changzhou Pharmaceutical Factory ChangzhouCN
CEP 2021-252 - Rev 01
Rivaroxaban
Nov 2025Inspected Apr 2025
Italy
NIFTY LABS PRIVATE LIMITED HyderabadIN
CEP 2022-375 - Rev 01
Rivaroxaban
Sept 2025—
DIVI'S LABORATORIES LIMITED HyderabadIN
CEP 2024-266 - Rev 00
Rivaroxaban
Aug 2025—
SHAOXING JINGXIN PHARMACEUTICAL CO., LTD. ShangyuCN
CEP 2020-327 - Rev 02
Rivaroxaban, Micronised, non-micronised
Jul 2025—
LEE PHARMA LIMITED HyderabadIN
CEP 2022-339 - Rev 01
Rivaroxaban
Jul 2025—
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Shenzhen CityCN
CEP 2024-239 - Rev 00
Rivaroxaban, Micronised
May 2025—
HIKAL LIMITED BangaloreIN
CEP 2023-351 - Rev 00
Rivaroxaban
Apr 2025Inspected Nov 2025
Switzerland
TAPI NL B.V. AmsterdamNL
CEP 2021-036 - Rev 02
Rivaroxaban
Mar 2025—
INDOCO REMEDIES LIMITED MumbaiIN
CEP 2022-159 - Rev 01
Rivaroxaban, Micronised
Dec 2024—
MEHTA API PVT. LTD. BoisarIN
CEP 2022-212 - Rev 01
Rivaroxaban
Dec 2024Inspected Oct 2024
Switzerland
MEGA FINE PHARMA PRIVATE LIMITED MumbaiIN
CEP 2024-353 - Rev 00
Rivaroxaban, Micronised, improved Process
Dec 2024—
INTAS PHARMACEUTICALS LIMITED AhmedabadIN
CEP 2020-178 - Rev 01
Rivaroxaban, Form-I, micronised
Nov 2024—
JIANGXI SYNERGY PHARMACEUTICAL CO., LTD. YichunCN
CEP 2021-047 - Rev 02
Rivaroxaban
Nov 2024—
MEDICHEM, S.A. Sant Joan DespíES
CEP 2024-317 - Rev 00
Rivaroxaban, RVXN
Oct 2024—
USV PRIVATE LIMITED MumbaiIN
CEP 2023-116 - Rev 01
Rivaroxaban, Micronised, Polymorphic Form-I
Oct 2024—
APITORIA PHARMA PRIVATE LIMITED HyderabadIN
CEP 2022-016 - Rev 00
Rivaroxaban
Aug 2024—
AMOLI ORGANICS PRIVATE LIMITED MumbaiIN
CEP 2022-474 - Rev 00
Rivaroxaban, Form-I
Jul 2024—
COHANCE LIFESCIENCES LIMITED MumbaiIN
CEP 2020-274 - Rev 02
Rivaroxaban
Jun 2024—
VASUDHA PHARMA CHEM LIMITED HyderabadIN
CEP 2022-397 - Rev 00
Rivaroxaban
Jun 2024—
MSN LABORATORIES PRIVATE LIMITED Rudraram VillageIN
CEP 2021-028 - Rev 01
Rivaroxaban, modification-I, micronised and non-micronised
Jun 2024—
MEDICHEM MANUFACTURING (MALTA) LTD. Hal FarMT
CEP 2021-005 - Rev 01
Rivaroxaban
Jan 2024Inspected Nov 2023
Malta
KRKA, d.d., Novo mesto Novo mestoSI
CEP 2021-231 - Rev 01
Rivaroxaban
Nov 2023Inspected Jul 2025
Slovenia
SRINI PHARMACEUTICALS PRIVATE LIMITED ChoutuppalIN
CEP 2021-466 - Rev 01
Rivaroxaban
Sept 2023Inspected Sept 2025
Sweden
MEGAFINE PHARMA (P) LIMITED MumbaiIN
R0-CEP 2021-277 - Rev 01
Rivaroxaban
Aug 2023—
CAMBREX PROFARMACO MILANO S.R.L. PaulloIT
R0-CEP 2022-314 - Rev 00
Rivaroxaban
Aug 2023—
BIOCON LIMITED BengaluruIN
R0-CEP 2022-144 - Rev 00
Rivaroxaban
Jul 2023—
ZHEJIANG GUOBANG PHARMACEUTICAL CO., LTD. ShangyuCN
R0-CEP 2021-389 - Rev 00
Rivaroxaban
Jun 2023—
ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD. Taizhou CityCN
R0-CEP 2020-330 - Rev 01
Rivaroxaban
Mar 2023—
CIPLA LIMITED MumbaiIN
R0-CEP 2021-278 - Rev 00
Rivaroxaban
Mar 2023—
BAYER AG LeverkusenDE
R0-CEP 2021-090 - Rev 00
Rivaroxaban, Micronised
Feb 2023—
INNOVARE LABS PRIVATE LIMITED VisakhapatnamIN
R0-CEP 2021-185 - Rev 00
Rivaroxaban
Jan 2023—
MOREPEN LABORATORIES LIMITED BaddiIN
R0-CEP 2021-369 - Rev 00
Rivaroxaban
Jan 2023—
ZHEJIANG LEPU PHARMACEUTICAL CO., LTD Taizhou CityCN
R0-CEP 2021-142 - Rev 00
Rivaroxaban
Nov 2022—
DR. REDDY'S LABORATORIES LIMITED HyderabadIN
R0-CEP 2020-250 - Rev 01
Rivaroxaban
Oct 2022—
RUYUAN HEC PHARM CO., LTD. ShaoguanCN
R0-CEP 2021-029 - Rev 00
Rivaroxaban
Mar 2022—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (2)

Organisations whose Type II DMFs for Rivaroxaban are no longer active. These show a past filing, not current supply.

Show all 2 historical records
  • Zhejiang Charioteer Pharmaceutical Co., Ltd.
    China · Inactive DMF 31900 · filed Jul 2017
  • Viwit Pharmaceutical Co., Ltd.
    China · Inactive DMF 28199 · filed Apr 2014

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (76 listed products contain Rivaroxaban). The latest listed patent expires 6 Aug 2044. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Rivaroxaban is an oral anticoagulant used to prevent and treat blood clots. It works as a direct factor Xa inhibitor, which disrupts the blood coagulation cascade.

Chemical identity

IUPAC name
5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide
Canonical SMILES
C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl
InChIKey
KGFYHTZWPPHNLQ-AWEZNQCLSA-N
Synonyms
(s)-rivaroxaban, bay-59-7939, bay59-7939, jnj-39039039, jnj39039039, xarelto

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Factor Xa Inhibitor
Mechanism of action
Factor Xa Inhibitors

Therapeutic areas

CardiovascularHematology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Rivaroxaban?

82 organisations hold an active US FDA Type II Drug Master File or a CEP for Rivaroxaban: Dr. Reddy's Laboratories Ltd. (India), Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), AMI LIFESCIENCES PRIVATE LTD (India), APITORIA PHARMA PRIVATE LTD (India), Bayer AG (Germany), Biocon Limited (India) and CHANGZHOU PHARMACEUTICAL FACTORY (China), and 74 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Rivaroxaban Drug Master Files are active?

Dr. Reddy's Laboratories Ltd. (DMF 41609, 28121), Alembic Pharmaceuticals Limited (DMF 28056), ALIVUS LIFE SCIENCES LTD (DMF 28864), AMI LIFESCIENCES PRIVATE LTD (DMF 37173), APITORIA PHARMA PRIVATE LTD (DMF 29048), Bayer AG (DMF 21581), Biocon Limited (DMF 35387) and CHANGZHOU PHARMACEUTICAL FACTORY (DMF 34436) and 53 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Rivaroxaban records mean?

2 organisations have only inactive Type II DMFs for Rivaroxaban. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Rivaroxaban have a European Certificate of Suitability?

Yes. 62 organisations hold a valid CEP for Rivaroxaban on the EDQM register, including GOLD PHARMA PRIVATE LIMITED Anakapalli District (IN), ZHEJIANG SYNCOTIDE BIO-PHARMACEUTICAL CO., LTD. Shaoxing (CN), MICRO LABS LIMITED Bengaluru (IN), TITAN PHARMAPLUS PRIVATE LIMITED Mahad (IN), MOEHS IBERICA S.L. Rubi (ES) and WANBURY LIMITED Thane (IN) and 55 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Rivaroxaban?

Yes. The latest patent listed for an approved US product containing Rivaroxaban expires 6 Aug 2044, across 76 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Rivaroxaban supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Rivaroxaban?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.